Filing Flows › Health Care › Biolife Solutions (BLFS)
Biolife Solutions (BLFS) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 6, 2026 · Biolife Solutions (BLFS) Q2 2026 earnings results →
Q2 2026 Revenue up 22% year over year to $28.5M · 158¢ of every $1 of revenue kept as net profit · operating margin 6.0%
Biolife Solutions made $28.5M in Q2 2026 (+22% Y/Y). Operating margin 6.0%, net earnings $45.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $28.5M in Q2 2026, up 21% year over year and up 4% from the previous quarter.
Gross margin was 64.2%, down 0.8 points from Q2 2025. Operating profit was $1.7M, a 6.0% margin (up 74.8 points year over year). Operating expenses fell 47% while revenue rose 21%. The fastest-growing cost line was Research & development (+51%). Net earnings were $45.1M. The tax line was a benefit of $42.4M on pre-tax earnings of $2.8M. Non-operating items added $1.1M, 38% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $6.3M (down 14% year over year), 14% of net earnings. Non-cash charges added back $411K of depreciation and amortization and $3.9M of share-based compensation. Working capital and other items used $43.0M. Capital expenditures of $1.0M left free cash flow of $5.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 6, 2026 | $28.5M | +22% | 6.0% | $45.1M | $6.3M |
| Q1 2026 | 10-Q | May 7, 2026 | $27.5M | +25% | 0.1% | $1.2M | −$491K |
| Q4 2025 | 10-K | Feb 26, 2026 | $18.8M | +24% | 7.2% | $11.1M | $4.9M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $28.1M | +31% | -0.3% | $621K | $6.1M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $25.4M | +29% | -63.4% | −$15.8M | $7.4M |
| Q1 2025 | 10-Q | May 8, 2025 | $23.9M | +30% | -5.1% | −$448K | $1.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Biolife Solutions
The following discussion of our business contains forward-looking statements that involve risks and uncertainties (see the section entitled “ Forward-Looking Statements ” herein). Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those factors set forth under “ Risk Factors ” and elsewhere in this Form 10-K. We are a life sciences company that develops, manufactures, and markets bioproduction products and services which are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. Our products are used in basic and applied research and commercial manufacturing of biologic-based therapies.
In its own words, from its 10-K, filed Feb 26, 2026.
Biolife Solutions against its Electromedical & Electrotherapeutic Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +22% against the peers' median +14%. Operating margin: 6.0% against the peers' median 6.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BLFS Biolife Solutions | Q2 2026 | $28.5M | +22% | 6.0% |
| MDT Medtronic | Q1 FY27 | $9.8B | +14% | 18.1% |
| ITGR Integer Holdings | Q3 2026 | $450M | -4% | 6.3% |
| LIVN LivaNova | Q3 2026 | $393M | +10% | 7.2% |
| CNMD Conmed | Q3 2026 | $336M | -0.7% | 11.1% |
| TMDX TransMedics Group | Q3 2026 | $203M | +41% | 13.9% |
| AXGN Axogen | Q3 2026 | $75.8M | +26% | 1.3% |
| OM Outset Medical | Q3 2026 | $33.6M | +14% | -36.5% |
| CBLL Ceribell | Q3 2026 | $29.3M | +30% | -70.0% |
Source: Biolife Solutions 10-Q on SEC EDGAR · CIK 834365 · Electromedical & Electrotherapeutic Apparatus
More on BLFS
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results